SCH772984

目录号:S7101

SCH772984 Chemical Structure

Molecular Weight(MW): 587.67

SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。

规格 价格 库存 购买数量  
RMB 2210.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • 293T cells were transfected with Flag-WT-FBW7. Thirty hours post transfection, cells were pretreated with MG132 and various MEK/ERK inhibitors overnight before harvesting. FBW7 phosphorylation status was examined by immunoblot analysis after immunoprecipitation.

    Cell Research, 2015, 25: 561-573. SCH772984 purchased from Selleck.

    K562 cells were exposed to ERK inhibitor SCH772984 (1 uM, 2 uM, 5 uM) for 48 h. Apoptosis was analyzed by Annexin V-APC labeling.

    Leuk Lymphoma 2014 1, 8. SCH772984 purchased from Selleck.

  • ERK1/2 influences the effects of TGF-β1 on Cdk5 and Bax in PC12 cells. A. Original western blot showing the level of Cdk5 and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. B. Arithmetic means ± SEM (n = 4) of Cdk5 protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. C. Original western blot showing the level of Bax and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) for 2 h. D. Arithmetic means ± SEM (n = 4) of Bax protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) for 2 h. **(p < 0.01), ***(p < 0.001) indicate statistically significant difference.

    Biochem Biophys Res Commun, 2017.. SCH772984 purchased from Selleck.

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述 SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。
特性 SCH772984不直接抑制MEK1, MEK2, BRAF, 或 CRAF酶活性。
靶点
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
体外研究

SCH772984是新型,选择性,ATP竞争性的ERK1/2抑制剂。SCH772984抑制ERK底物p90核糖体S6激酶(T359/S363 磷酸化-RSK)的磷酸化,这种作用存在剂量依赖性。SCH772984也能抑制ERK自身活化环中残基的磷酸化。SCH772984分别抑制约88%和49%BRAF突变型或RAS-突变型肿瘤细胞系,EC50值<500 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS5TWM2OD1yLkK0JI5O NUjJRoV7OjV|NUC5N|E>
WM-266-4 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VPGpKSzVyPUKwJI5O NF\3XmMzOzZzNEi5PC=>
UACC-62 NGK2Zm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TZXGlEPTB;M{Cgcm0> NFHlcpQzOzZzNEi5PC=>
Colo-205 M3XvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\oeXFKSzVyPUO2JI5O MUSyN|YyPDh7OB?=
SK-Mel-1 NEHSeVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P3PGlEPTB;M{egcm0> NYO4ZYFPOjN4MUS4PVg>
WiDr NYri[lBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN7IH7N M4ruS|I{PjF2OEm4
M14 M3qyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fRfWlEPTB;NEegcm0> M1nCRlI{PjF2OEm4
HT-29 NXXYZXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XuNGlEPTB;NUCgcm0> MYeyN|YyPDh7OB?=
8505C MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvtU4ZKSzVyPUWwJI5O NHTseIwzOzZzNEi5PC=>
HT-144 NX;SVWpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWxR2VKSzVyPU[wJI5O NYXnZZJZOjN4MUS4PVg>
SK-Mel-5 NI\L[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Lm[WlEPTB;Nk[gcm0> M1vRZVI{PjF2OEm4
A375-SM NV\PVFE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXtTWM2OD15NTDuUS=> NEjDRYMzOzZzNEi5PC=>
SK-Mel-28 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHZRXpKSzVyPUi1JI5O MUCyN|YyPDh7OB?=
LOX NWTsUWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuN2JKSzVyPUGwNEBvVQ>? NVTpfnJ5OjN4MUS4PVg>
SK-Mel-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFzODDuUS=> MYqyN|YyPDh7OB?=
K1 M{P3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y1O2lEPTB;MUOwJI5O M4XERlI{PjF2OEm4
Hs-695T MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF4NTDuUS=> Mke4NlM3OTR6OUi=
BHT-101 NFWweFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4POc2lEPTB;M{CwJI5O NHy3RZozOzZzNEi5PC=>
RPMI-7951 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\rfGlEPTB;M{S0JI5O NYCyOnA{OjN4MUS4PVg>
A2058 NEHMc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXiwdHNsUUN3ME2zOlAhdk1? MUSyN|YyPDh7OB?=
SK-Hep-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF2MkKgcm0> M2HpdlI{PjF2OEm4
A673 NWLJcpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITuVpNKSzVyPUOwNFEhdk1? MUmyN|YyPDh7OB?=
DBTRG-05MG MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjiTWM2OD1|MECxJI5O MkTwNlM3OTR6OUi=
SW-626 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf4TWM2OD1|MzDuUS=> NIjvVoEzOzZzNEi5PC=>
LoVo M2r5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki2TWM2OD12NzDuUS=> MVWyN|YyPDh7OB?=
MiaPaCa NFvjZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTV|IH7N MkjWNlM3OTR6OUi=
SW-620 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjsTVlKSzVyPUGwOEBvVQ>? NICw[I0zOzZzNEi5PC=>
CAPAN-1 NVPGTWVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7yeodKSzVyPUGwOEBvVQ>? M{Lh[VI{PjF2OEm4
SW-527 NWfTPFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvWTWM2OD1zMkGgcm0> NHHte4YzOzZzNEi5PC=>
HCT-116 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fodGlEPTB;MUK4JI5O NVW5c|d7OjN4MUS4PVg>
SW-480 M3zBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrhTWM2OD1zNkWgcm0> MYeyN|YyPDh7OB?=
HPAC NIH3fpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPHTWM2OD1zN{Cgcm0> NEXkb2czOzZzNEi5PC=>
OVCAR-5 NVPuPGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nodmlEPTB;MkC4JI5O NHLVfFYzOzZzNEi5PC=>
AsPc-1 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7vNVhrUUN3ME2yO|Ahdk1? MWqyN|YyPDh7OB?=
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDlVWl{UUN3ME2zNlYhdk1? MWSyN|YyPDh7OB?=
SNU-1 NHvSS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GbVlKSzVyPUO1OEBvVQ>? M3ywN|I{PjF2OEm4
HOP62 M1jVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW3co14UUN3ME22O|Yhdk1? NFTnVnYzOzZzNEi5PC=>
H23 M1Phc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCwfXhUUUN3ME2xNFAxKG6P MXKyN|YyPDh7OB?=
MB-231 M3PRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFyMECgcm0> MoDZNlM3OTR6OUi=
SU.86.86 NUPPc2R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFyMEGgcm0> MoK0NlM3OTR6OUi=
CFPAC-1 NInMT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XUPGlEPTB;MUCwNUBvVQ>? MXWyN|YyPDh7OB?=
A427 NEDyd|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrFTWM2OD1zNEOzJI5O NU\x[npLOjN4MUS4PVg>
MDAH-2774 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHQTWM2OD1{NkW3JI5O NVj1Z|NqOjN4MUS4PVg>
NCI-H157 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLJfGFKSzVyPUOwNFAhdk1? Moe0NlM3OTR6OUi=
HTB-177 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f4dGlEPTB;M{CwNEBvVQ>? MYOyN|YyPDh7OB?=
UM-UC-3 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKwNZVzUUN3ME2zNFAyKG6P MofJNlM3OTR6OUi=
HCT-8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonVTWM2OD1|MECxJI5O Moq3NlM3OTR6OUi=
Panc-1 M3rye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTjTWM2OD1|MECxJI5O NWrrSGg1OjN4MUS4PVg>
DLD-1 NIrGdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LQNWlEPTB;M{CwNUBvVQ>? MYGyN|YyPDh7OB?=
HCT-15 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNyMEGgcm0> NU[5boJzOjN4MUS4PVg>
HL-60 NXXkR|hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfBRo03UUN3ME2zNEBvVQ>? MlLCNlM3OTR6OUi=
SK-Mel-2 M1HaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfqcWM6UUN3ME2zOEBvVQ>? MnflNlM3OTR6OUi=
RD NXHzNlY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O0WGlEPTB;MUKzJI5O MUSyN|YyPDh7OB?=
HT-1197 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;pdlNXUUN3ME2zNVYhdk1? NUfZSopVOjN4MUS4PVg>
Molt-3 NUHoW2liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPnTZdZUUN3ME22NFAhdk1? NYezdFRSOjN4MUS4PVg>
PA-1 NXjmdJlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLSVlVKSzVyPUGwNFEhdk1? NU\CRmFzOjN4MUS4PVg>
Molt-4 NXzKZpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f2bmlEPTB;M{CwNUBvVQ>? M{P3RlI{PjF2OEm4
NCI-H292 NUXjOVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTlyIH7N MXGyN|YyPDh7OB?=
A2780 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7aTWM2OD1zNEOgcm0> M4eyelI{PjF2OEm4
IGROV-1 NGXmTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7LWmFKSzVyPUG0OkBvVQ>? MVGyN|YyPDh7OB?=
SK-N-SH NV;CbIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHsTWM2OD1zNUCgcm0> NGT4PWIzOzZzNEi5PC=>
N-87 NF3oPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGflOXNKSzVyPUOwO{BvVQ>? MlLVNlM3OTR6OUi=
H322 NInZfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu2OlFKSzVyPUOyOUBvVQ>? NHTr[VIzOzZzNEi5PC=>
H716 NETPNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN|NDDuUS=> MmrhNlM3OTR6OUi=
TT M3XRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXDTWM2OD12ME[gcm0> NHnLd2gzOzZzNEi5PC=>
Caki-1 M1qwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\tTWM2OD12NUCgcm0> M4rsfFI{PjF2OEm4
5637 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\ydIpiUUN3ME22NVAhdk1? NGfHfoozOzZzNEi5PC=>
MB-453 NUDKfFVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjVT2hXUUN3ME22O|Ihdk1? M3ntVlI{PjF2OEm4
RT-4 M{W1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;QN2lEPTB;OEGwJI5O MWKyN|YyPDh7OB?=
HOP92 NEPCRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofwTWM2OD16MkCgcm0> NHTSbHczOzZzNEi5PC=>
KG-1 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGxTWM2OD17MECgcm0> MXuyN|YyPDh7OB?=
Hs-294T MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfKZY9LUUN3ME25OFUhdk1? NV7nc3lFOjN4MUS4PVg>
SF-539 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjRWlEPTB;MUCwNEBvVQ>? NH[xfFkzOzZzNEi5PC=>
U-251 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjIXI5bUUN3ME2xNFAxKG6P NWTQR2tuOjN4MUS4PVg>
MB-468 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn5NZJDUUN3ME2xNFAxKG6P NH\NNYUzOzZzNEi5PC=>
HS746T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ITWM2OD1zMECwJI5O NV;YUYNbOjN4MUS4PVg>
SCABER MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iwXmlEPTB;MUCwNEBvVQ>? MmHRNlM3OTR6OUi=
MCF-7 NUDM[JE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzFbXFKSzVyPUGwNFEhdk1? MoqxNlM3OTR6OUi=
CHL-1 NW\yNms6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTrTWM2OD1zNE[wJI5O NHPCRlMzOzZzNEi5PC=>
U87MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\uT2tKSzVyPUKwNFAhdk1? NWDOUXRPOjN4MUS4PVg>
SJCRH30 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJyMEKgcm0> NFS2RZYzOzZzNEi5PC=>
ES-2 MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLONmpQUUN3ME2yOlU6KG6P NFPDeo4zOzZzNEi5PC=>
HT-1376 M1S4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KxUGlEPTB;MkiwNEBvVQ>? NVTOXVZoOjN4MUS4PVg>
A172 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNyMECgcm0> M2HndVI{PjF2OEm4
769P NF7LPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrvTWM2OD1|MECwJI5O MlLzNlM3OTR6OUi=
NCI-H520 NFXiPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNyMECgcm0> NY\ONXdGOjN4MUS4PVg>
DU145 M17ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNyMECgcm0> MmXwNlM3OTR6OUi=
K562 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjt[FBKSzVyPUOwNFAhdk1? NHjZO3AzOzZzNEi5PC=>
U-937 NY\PUlZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNyMECgcm0> MoK3NlM3OTR6OUi=
A204 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq5SHpKSzVyPUOwNFEhdk1? M1PDdlI{PjF2OEm4
DAOY MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TmRmlEPTB;M{CwNUBvVQ>? M2DFXlI{PjF2OEm4
SF-268 NG\QfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNyMEGgcm0> NFL5WWQzOzZzNEi5PC=>
SF-295 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DKSWlEPTB;M{CwNUBvVQ>? NIDwbGMzOzZzNEi5PC=>
SNB-19 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXEc3p2UUN3ME2zNFAyKG6P Mm\zNlM3OTR6OUi=
SNB-75 M2XU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLkV5RKSzVyPUOwNFEhdk1? M3TSOlI{PjF2OEm4
U373-MG M2Oyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfnW5lCUUN3ME2zNFAyKG6P NVnKeJVEOjN4MUS4PVg>
786-O NUnJVlhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTNyMEGgcm0> NWTmb5J2OjN4MUS4PVg>
A498 M4[w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLwTWM2OD1|MECxJI5O NWLMbpRwOjN4MUS4PVg>
ACHN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzpU4ZUUUN3ME2zNFAyKG6P NYPXcXpbOjN4MUS4PVg>
EKVX NHS3O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfsUZM{UUN3ME2zNFAyKG6P MlXaNlM3OTR6OUi=
H226 NHTpW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O5WGlEPTB;M{CwNUBvVQ>? MlTGNlM3OTR6OUi=
H522 NXvmUJFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XwRmlEPTB;M{CwNUBvVQ>? NW\Ye3ZkOjN4MUS4PVg>
HeLa MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNyMEGgcm0> NYfxeYM3OjN4MUS4PVg>
SK-OV-3 NGTzN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;uSotKSzVyPUOwNFEhdk1? MkX6NlM3OTR6OUi=
Ln Cap M13XcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X6VWlEPTB;M{CwNUBvVQ>? NVq0RodyOjN4MUS4PVg>
PC3 M1S4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNyMEGgcm0> MViyN|YyPDh7OB?=
SNU-16 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn3bVdKSzVyPUOwNFEhdk1? MmPLNlM3OTR6OUi=
FTC-133 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNyMEGgcm0> NHXqTZQzOzZzNEi5PC=>
Ro82-W-1 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTi[mFKSzVyPUOwNFEhdk1? MX6yN|YyPDh7OB?=
Daudi M{DwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnMTWM2OD1|MECxJI5O MWCyN|YyPDh7OB?=
Jijoye NFTWRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNyMEGgcm0> NHzEXVgzOzZzNEi5PC=>
Jurkat M4e1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTuTWM2OD1|MECxJI5O MYeyN|YyPDh7OB?=
J-82 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TsVmlEPTB;M{CwNUBvVQ>? MlPiNlM3OTR6OUi=
TCC-SUP MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvNTmhKSzVyPUOwNFEhdk1? NEn4S3EzOzZzNEi5PC=>
BT-474 NEDBTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP4TWM2OD1|MECxJI5O NILMNnkzOzZzNEi5PC=>
ZR-75-1 M2TFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXNfFFVUUN3ME2zNFAyKG6P M3vwdFI{PjF2OEm4

... Click to View More Cell Line Experimental Data

体内研究 SCH772984按耐受剂量处理移植瘤模型,诱导肿瘤衰退。SCH772984作用于抗BRAF或MEK抑制剂的模型,有效抑制MAPK信号和细胞增殖。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

ERK2 IMAP 酶实验:

SCH772984作用于纯化的ERK2或ERK1,按一式两份进行8点稀释曲线。酶添加到实验板中。与化合物温育,然后加入底物肽和ATP溶液中。384孔板中每孔加入14μl稀释的酶(每组反应含0.3ng活性ERK2)。实验板轻轻震荡混合试剂,然后在室温下温育45分钟。加入60μl of IMAP 结合溶液 (IMAP珠在1X结合缓冲液中按1:2200稀释)终止反应。实验板在室温下再温育0.5小时,使磷酸肽与IMAP珠完全结合。然后在 LJL分析仪上读数。
细胞实验:

[1]

+ 展开
  • Cell lines: BRAF突变型或 RAS突变型肿瘤系
  • Concentrations: ~10 μM
  • Incubation Time: 5 天
  • Method:

    在96孔板中进行细胞增殖实验,细胞按每孔 4,000个的密度接种。接种24小时后,使用DMSO处理细胞,9点IC50稀释 (0.001-10 μM) ,DMSO终浓度为1%。使用ViaLight发光试剂盒5天后,测定存活力。细胞系存活力检测中,使用SCH772984处理细胞4天,然后进行CellTiterGlo发光细胞活力检测。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 裸鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品:
5% DMSO+30% PEG 300+ddH2O
0.6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 587.67
化学式

C33H33N9O2

CAS号 942183-80-4
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • 回答:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

Related Antibodies

ERK Signaling Pathway Map

Tags: 购买SCH772984 | SCH772984供应商 | 采购SCH772984 | SCH772984价格 | SCH772984生产 | 订购SCH772984 | SCH772984代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID